The changing pattern of coronary perforation during percutaneous coronary intervention in the New Device Era

Journal of Invasive Cardiology

Volumn 16, Issue 6, 2004, Pages 297-301

  Witzke, Christian F ^a   Martin Herrero, Francisco ^a   Clarke, Sarah C ^a   Pomerantzev, Eugene ^a   Palacios, Igor F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical outcomes; Coronary perforation; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; FIBRINOGEN RECEPTOR;

ADULT; AGED; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; CORONARY ARTERY PERFORATION; CORONARY STENT; DEATH; DEVICE; EARLY DIAGNOSIS; EMERGENCY SURGERY; EXTRAVASATION; FEMALE; GUIDE WIRE; HEART INFARCTION; HEART TAMPONADE; HEMODYNAMICS; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MALE; PERICARDIAL EFFUSION; Q WAVE; THROMBOCYTE TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT OUTCOME; ATHERECTOMY; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; INJURY; METHODOLOGY; PENETRATING TRAUMA; RISK FACTOR; STENT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHERECTOMY, CORONARY; CORONARY VESSELS; FEMALE; HUMANS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; STENTS; WOUNDS, PENETRATING;

EID: 2642510624     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kimbiris D, Iskandrian AS, Goel I, et al. Transluminal coronary angioplasty complicated by coronary perforation. Cathet Cardiovasc Diagn 1982;8:481-487.
2. Ajluni SC, Glazier S, Blankenship L, et al. Perforations after percutaneous coronary intervention: Clinical, angiographic and therapeutic observations. Cathet Cardiovasc Diagn 1994;32:206-212.
3. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new device era. Incidence, classification, management and outcome. Circulation 1994;90:2725-2730.
4. Dippel EJ, Kereiakes DJ, Tramuta DA, et al. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management. Cathet Cardiovasc Intervent 2001;52:279-286.
5. Gruberg L, Pinnow E, Flood R, et al. Incidence, management and outcome of coronary artery perforation during percutaneous coronary intervention. Am J Cardiol 2000;86:680-682.
6. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on the Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-545.
7. Ellis S, Vandormael M, Cowley M, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193-1202.
8. Foley DP, Escaned J, Strauss BH, et al. Quantitative coronary angiography (QCA) in interventional cardiology: Clinical applications of QCA measurements. Prog Cardiovasc Dis 1994;36:363-384.
9. Van der Zwet PM, Reiber JH. Issues of QCA validation. Cathet Cardiovasc Diagn 1994;33:97-98.
10. Bittl J, Ryan T, Keaney J, et al. Coronary artery perforation during excimer laser coronary angioplasty. J Am Coll Cardiol 1993;21:1158-1165.
11. Nashed G, French B, Gallagher D, et al. Right ventricular perforation with cardiac tamponade associated with use of a temporary pacing wire and abciximab during complex coronary angioplasty. Cathet Cardiovasc Intervent 1999;48:388-389.
12. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
13. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
14. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The Capture Study. Lancet 1997;349:1429-1435.
15. The EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
16. Briguori C, Di Mario C, De Gregorio J, et al. Administration of protamine after coronary scent deployment. Am Heart J 1999;138:64-68.
17. Briguori C, Angelo A, Nishida T, et al. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures. Circulation 2000;102:3028-3031.
18. Caputo R, Amin N, Marvasti M, et al. Successful treatment of a saphenous vein graft perforation with an autologous vein-covered stent. Cathet Cardiovasc Intervent 1999;48:382-386.
19. Pienvichit P, Waters J. Successful closure of coronary artery perforation using makeshift stent sandwich. Cathet Cardiovasc Intervent 2001;54:209-213.
20. Assali A, Moustapha A, Sdringola S, et al. Successful treatment of coronary artery perforation in an abciximab-treated patient by microcoil embolization.